Biogen Inc. — Q2 2022 Form 10-Q
Reporting period: Quarter and six months ended June 30, 2022. Unaudited consolidated results; Biogen reports one operating segment. Dollar amounts are in millions except per-share data.
Business context
Biogen develops and commercializes therapies focused primarily on neuroscience, including multiple sclerosis (MS) and spinal muscular atrophy (SMA), and has financial interests in anti-CD20 programs. Its portfolio also includes biosimilars. The filing describes pressure from generic and biosimilar competition, pricing and reimbursement constraints, and the need for successful pipeline launches to support longer-term growth.
Key financial metrics
| Metric | Q2 2022 | Q2 2021 | Six months 2022 | Six months 2021 |
|---|---|---|---|---|
| Total revenue | $2,589.1 | $2,775.0 | $5,120.9 | $5,469.0 |
| Income before income taxes and equity in investee loss | $1,269.5 | $582.1 | $1,616.9 | $1,049.1 |
| Net income attributable to Biogen | $1,058.0 | $448.5 | $1,361.8 | $858.7 |
| Diluted EPS attributable to Biogen | $7.24 | $2.99 | $9.27 | $5.68 |
| Operating cash flow | Not separately stated | Not separately stated | $898.3 | $1,996.3 |
Q2 revenue declined 6.7% year over year; product revenue fell 8.1%. Q2 net income attributable to Biogen was approximately 40.9% of revenue, a derived measure materially affected by unusual items described below. The filing does not provide a clear comparable operating-margin figure in the supplied text.
- Revenue mix, Q2: Product revenue was $2,054.9; anti-CD20 program revenue was $436.3; other revenue was $97.9.
- Liquidity at June 30: Cash and cash equivalents were $2,646.6; marketable securities totaled $3,254.2; together, $5,900.8. Working capital was $4,722.9, versus $3,558.3 at year-end 2021.
- Debt: Notes payable totaled $7,277.2, including $999.8 current. Cash and marketable securities exceeded notes payable by about $1,376.4, a derived comparison. Biogen redeemed the $1.0 billion notes due September 2022 in July 2022.
- Cash flows, six months: Investing activities provided $45.5, including Samsung Bioepis sale proceeds; financing activities used $488.0, including $500.0 of share repurchases. Capital expenditures were $94.8.
- Margins and costs: Q2 total cost and expense was $1,319.6 versus $2,192.9 a year earlier, largely reflecting lower prior-year impairment charges and the net impact of major items in other income/expense. Six-month cost of sales rose to $1,237.9 from $937.8, mainly due to ADUHELM inventory and capacity charges.
Material changes versus the prior comparable period
- Product revenue decreased $181.1 in Q2, led by MS revenue down $102.6 and SPINRAZA down $68.6. TECFIDERA sales faced generic competition; SPINRAZA was affected by competition, pricing, shipment timing and foreign exchange.
- Q2 results included a pretax gain of about $1.5 billion from selling Biogen’s 49.9% Samsung Bioepis interest and a $900.0 million charge for an agreement in principle to resolve qui tam litigation. These items substantially influenced reported earnings and other income/expense.
- ADUHELM revenue remained minimal. The CMS coverage decision limits Medicare access to patients in qualifying clinical trials; Biogen expects future demand to be minimal. In Q1 it recorded about $275 million of gross ADUHELM inventory and purchase-commitment charges plus about $45 million of idle-capacity charges, with Eisai sharing a portion.
- Biogen sold its Samsung Bioepis stake in April for approximately $1.0 billion cash at closing, with about $1.3 billion of additional deferred payments expected over two years and up to $50 million in commercial milestones. The sale generated the reported gain; the deferred receivables’ fair value was about $1.2 billion at June 30.
- Q2 restructuring charges were $70.6 million; six-month charges were $108.7 million. The company expects total 2022 charges of approximately $130–$150 million from workforce reductions, ADUHELM infrastructure reductions, real estate consolidation and efficiencies.
Outlook, commentary and risks
- The filing gives no clear numerical full-year revenue or EPS guidance in the supplied text. Management expects TECFIDERA revenue to continue declining in 2022; Interferon revenue to decline; TYSABRI revenue to be relatively flat; SPINRAZA to face continued competition; and biosimilar revenue to decline slightly despite the BYOOVIZ U.S. launch.
- Management expects 2022 SG&A expense to decline versus 2021, primarily from cost savings and reduced ADUHELM commercialization infrastructure. Excluding prior-year upfront payments, core R&D expense was expected to be consistent with 2021 as the company continued pipeline investment.
- Lecanemab: Eisai submitted a BLA for accelerated approval in May 2022; FDA acceptance and Priority Review, with a January 6, 2023 action date, were reported in July. Biogen and Eisai share costs and potential profits equally. Inventory on hand could be expensed if the program fails to gain approval or has an adverse clinical outcome.
- Zuranolone: Biogen and Sage planned to complete a single NDA submission for major depressive disorder and postpartum depression in the second half of 2022 and seek Priority Review, following positive Phase 3 postpartum depression results.
- Material risks include competition and pricing/reimbursement pressure; ADUHELM’s restricted Medicare coverage and required confirmatory trial; patent disputes, including TECFIDERA and TYSABRI matters; clinical and regulatory uncertainty; manufacturing and supply constraints; foreign exchange and investment-value volatility; and effects of COVID-19 and the Ukraine conflict on trials and operations.
- The $900 million litigation agreement in principle remained subject to final settlement documents and agreements with government entities, with no admission of liability. Biogen said payment plus fees and expenses would materially affect cash flow when paid. Other legal matters include ADUHELM-related securities suits and government investigations; possible losses in several matters could not be estimated.
Most important facts for investors to verify
- Whether the Samsung BioLogics deferred payments are received on schedule and whether any commercial milestones are achieved.
- Final terms, timing and cash impact of the proposed $900 million qui tam settlement, including fees and expenses.
- ADUHELM’s future demand, costs and confirmatory-trial progress under the CMS coverage restrictions.
- Pipeline milestones and regulatory outcomes for lecanemab and zuranolone, and potential inventory or development-cost consequences.
- Whether generic competition, particularly for TECFIDERA, and competition for SPINRAZA and anti-CD20 products continue to reduce revenue and operating cash flow.